Furthermore, in a cross-sectional study involving 346 individuals with type 2 diabetes and biopsy-proven NAFLD, multivariate models analysis showed that treatment with insulin (but not metformin) was significantly associated with a higher prevalence of NASH (OR 2.24, p = 0.025) but not fibrosis [11]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.